← All Posts
LGN
Ligand Pharmaceuticals Incorporated
June 06, 2026
•
Author: Phil Ratcliff
•
LGND
| Item |
Proposal |
Vote |
| 1 |
Election of Directors |
|
| 1.01 |
Jason M. Aryeh |
✓ For(15.349)
|
| 1.02 |
Todd C. Davis |
Withhold(15.349)
|
| 1.03 |
Nancy R. Gray, Ph.D. |
✓ For(15.349)
|
| 1.04 |
Jason Haas |
✓ For(15.349)
|
| 1.05 |
John W. Kozarich, Ph.D. |
✓ For(15.349)
|
| 1.06 |
John L. LaMattina, Ph.D. |
✓ For(15.349)
|
| 1.07 |
Stephen L. Sabba, M.D. |
✓ For(15.349)
|
| 1.08 |
Martine Zimmermann, Pharm.D. |
✓ For(15.349)
|
| 2 |
Ratification of Ernst & Young LLP as Ligand’s independent registered accounting firm |
✓ For(15.349)
|
| 3 |
Approval, on an advisory basis, of the compensation of the named executive officers |
✓ For(15.349)
|
| 4 |
Approval of an amendment and restatement of Ligand’s 2002 Stock Incentive Plan |
✓ For(15.349)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial